BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 25398814)

  • 1. Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor.
    Gaur S; Torabi AR; Corral J
    In Vivo; 2014; 28(6):1149-53. PubMed ID: 25398814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
    Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
    Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
    Soverini S; De Benedittis C; Papayannidis C; Paolini S; Venturi C; Iacobucci I; Luppi M; Bresciani P; Salvucci M; Russo D; Sica S; Orlandi E; Intermesoli T; Gozzini A; Bonifacio M; Rigolin GM; Pane F; Baccarani M; Cavo M; Martinelli G
    Cancer; 2014 Apr; 120(7):1002-9. PubMed ID: 24382642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia?].
    Thomas X
    Bull Cancer; 2011 Jul; 98(7):761-7. PubMed ID: 21700550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status.
    Kawajiri C; Tanaka H; Hashimoto S; Takeda Y; Sakai S; Takagi T; Takeuchi M; Ohwada C; Sakaida E; Shimizu N; Nakaseko C
    Int J Hematol; 2014 Apr; 99(4):513-8. PubMed ID: 24532437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Jabbour E; Cortes J; Kantarjian H
    Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
    Sherbenou DW; Wong MJ; Humayun A; McGreevey LS; Harrell P; Yang R; Mauro M; Heinrich MC; Press RD; Druker BJ; Deininger MW
    Leukemia; 2007 Mar; 21(3):489-93. PubMed ID: 17252009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid.
    Sanchez R; Ayala R; Alonso RA; Martínez MP; Ribera J; García O; Sanchez-Pina J; Mercadal S; Montesinos P; Martino R; Barba P; González-Campos J; Barrios M; Lavilla E; Gil C; Bernal T; Escoda L; Abella E; Amigo ML; Moreno MJ; Bravo P; Guàrdia R; Hernández-Rivas JM; García-Guiñón A; Piernas S; Ribera JM; Martínez-López J
    Ann Hematol; 2017 Jul; 96(7):1069-1075. PubMed ID: 28451802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolated central nervous system relapse in patient with blast-crisis chronic myeloid leukemia in durable complete cytogenetic remission on dasatinib treatment: pharmacokinetics and ABL mutation analysis in cerebrospinal fluid.
    Zhou HS; Dai M; Wei Y; Wang Q; Xu N; Yin C; Meng F
    Leuk Lymphoma; 2013 Jul; 54(7):1557-9. PubMed ID: 23194002
    [No Abstract]   [Full Text] [Related]  

  • 20. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.